Senores Pharmaceuticals Ltd Stock Price Today (NSE: SENORES)
Fundamental Score
Senores Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Senores Pharmaceuticals Ltd share price today is ₹759.60, up +0.92% on NSE/BSE as of 30 March 2026. Senores Pharmaceuticals Ltd (SENORES) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.72K (Cr). The 52-week high for SENORES share price is ₹876.50 and the 52-week low is ₹440.30. At a P/E ratio of 42.68x, SENORES is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.82% and a debt-to-equity ratio of 0.30.
Senores Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Senores Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Senores Pharmaceuticals Share Price: A Conservative Investor's Perspective
The pharmaceutical industry, while defensive, is increasingly facing pricing pressures and heightened regulatory scrutiny, demanding meticulous financial analysis. This report analyzes "Senores Pharmaceuticals share price" (₹825.30) from a conservative value investing standpoint, prioritizing capital safety and long-term sustainability. A key metric under scrutiny is the Price-to-Earnings (PE) ratio of 42.68. This is considerably higher than what a conservative investor typically seeks, signaling potential overvaluation. We will analyze this in context of the company's Return on Capital Employed (ROCE) and peer performance.
Senores Pharmaceuticals Ltd boasts an ROCE of 11.4%. While positive, it doesn't immediately indicate a wide economic moat. A truly durable moat allows a company to consistently generate above-average returns, shielding it from competition. The 11.4% ROCE suggests the company might face challenges in maintaining its competitive position over the long term, especially if competitors can replicate its products or processes with similar efficiency. Continuous monitoring of ROCE trends will be crucial.
Comparing Senores Pharmaceuticals with its peers provides valuable context. For instance,
Mankind Pharma Ltd often commands a premium valuation due to perceived superior management quality and brand strength. A detailed assessment of Senores' management track record, capital allocation decisions, and corporate governance practices is essential to justify its current PE ratio. While comparing numbers is useful, qualitative aspects like management competency can significantly impact long-term shareholder value, and such aspects are notoriously difficult to quantify, requiring further intensive study.Ultimately, a conservative investment approach emphasizes prudence. While Senores Pharmaceuticals shows some positive signs, the relatively high PE ratio coupled with a moderate ROCE necessitates cautious consideration. Further investigation into the company's growth prospects, debt levels, and ability to sustain its ROCE is warranted before making any investment decisions. This analysis forms part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, focusing on identifying potential risks and opportunities from a value investor's perspective.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Senores Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SENORES across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (152.18%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (60.75%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.30)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (5.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 42.68x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Senores Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Senores Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About SENORES (Senores Pharmaceuticals Ltd)
Senores Pharmaceuticals Ltd is a global pharmaceutical company dedicated to advancing healthcare through the discovery, development, and commercialization of innovative therapies. ...With a strong emphasis on research and development, Senores Pharmaceuticals is committed to addressing unmet medical needs across a broad range of therapeutic areas. The company's mission is to improve patient outcomes and enhance the quality of life for individuals worldwide by providing access to safe, effective, and affordable medicines. Senores Pharmaceuticals operates with the highest ethical standards and a focus on sustainability, ensuring that its business practices are environmentally responsible and socially conscious. They strive to be a trusted partner for healthcare professionals and patients, offering comprehensive support and resources to optimize treatment outcomes. Driven by a passion for scientific excellence, Senores Pharmaceuticals invests heavily in cutting-edge technologies and strategic collaborations to accelerate the development of novel therapeutics. The company's robust pipeline includes a diverse portfolio of products in various stages of development, targeting diseases with significant unmet needs. Senores Pharmaceuticals is committed to bringing innovative solutions to market that transform the lives of patients. Their experienced team of scientists, clinicians, and business professionals work collaboratively to navigate the complex regulatory landscape and ensure the timely delivery of high-quality products to patients in need. Senores Pharmaceuticals is dedicated to fostering a culture of innovation, collaboration, and patient-centricity, where every employee is empowered to make a difference in the world. Senores Pharmaceuticals is focused on expanding its global reach and strengthening its presence in key markets. The company's commercial operations are supported by a dedicated sales and marketing team that is committed to providing healthcare professionals with the information and resources they need to make informed treatment decisions. Senores Pharmaceuticals has established a strong distribution network to ensure that its products are readily available to patients around the world. In addition to its own product portfolio, Senores Pharmaceuticals is actively seeking partnerships and licensing agreements to expand its offerings and address a wider range of medical needs. The company is dedicated to building long-term relationships with healthcare providers, payers, and patient advocacy groups to improve access to care and promote positive health outcomes.
Company Details
Key Leadership
SENORES Share Price: Frequently Asked Questions
What is the current share price of Senores Pharmaceuticals Ltd (SENORES)?
As of 30 Mar 2026, 12:02 pm IST, Senores Pharmaceuticals Ltd share price is ₹759.60. The SENORES stock has a market capitalisation of ₹3.72K (Cr) on NSE/BSE.
Is SENORES share price Overvalued or Undervalued?
SENORES share price is currently trading at a P/E ratio of 42.68x, compared to the industry average of 31.77x. Based on this relative valuation, the Senores Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SENORES share price?
The 52-week high of SENORES share price is ₹876.50 and the 52-week low is ₹440.30. These values are updated daily from NSE/BSE price data.
What factors affect the Senores Pharmaceuticals Ltd share price?
Key factors influencing SENORES share price include quarterly earnings growth (Sales Growth: 60.75%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Senores Pharmaceuticals Ltd a good stock for long-term investment?
Senores Pharmaceuticals Ltd shows a 5-year Profit Growth of N/A% and an ROE of 11.82%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.30 before investing in SENORES shares.
How does Senores Pharmaceuticals Ltd compare with its industry peers?
Senores Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare SENORES share price P/E of 42.68x and ROE of 11.82% against the industry averages to determine competitive standing.
What is the P/E ratio of SENORES and what does it mean?
SENORES share price has a P/E ratio of 42.68x compared to the industry average of 31.77x. Investors pay ₹43 for every ₹1 of annual earnings.
How is SENORES performing according to Bull Run's analysis?
SENORES has a Bull Run fundamental score of 38.9/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SENORES belong to?
SENORES operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Senores Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for SENORES?
SENORES has an ROE of 11.82%, which shows decent profitability but room for improvement. ROE measures how efficiently Senores Pharmaceuticals Ltd generates profits from shareholders capital.
How is SENORES debt-to-equity ratio and what does it indicate?
SENORES has a debt-to-equity ratio of 0.30, which indicates conservative financing with low financial risk.
What is SENORES dividend yield and is it a good dividend stock?
SENORES offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Senores Pharmaceuticals Ltd shares.
How has SENORES share price grown over the past 5 years?
SENORES has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in SENORES and why does it matter?
Promoters hold 45.80% of SENORES shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Senores Pharmaceuticals Ltd.
What is SENORES market capitalisation category?
SENORES has a market capitalisation of ₹3718 crores, placing it in the Small-cap category.
How volatile is SENORES stock?
SENORES has a beta of N/A. A beta > 1 suggests the Senores Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SENORES operating profit margin trend?
SENORES has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is SENORES quarterly performance?
Recent quarterly performance shows Senores Pharmaceuticals Ltd YoY Sales Growth of 60.75% and YoY Profit Growth of 152.18%.
What is the institutional holding pattern in SENORES?
SENORES has FII holding of 4.28% and DII holding of 8.62%. Significant institutional holding often suggests professional confidence in the Senores Pharmaceuticals Ltd stock.